Advertisement

Fenoldopam for the prevention of contrast-induced nephropathy (CIN)—do we need more trials? A meta-analysis

  • Muhammad Naeem
    Correspondence
    Corresponding author. 593 Eddy Street, 338 Gerry House, Rhode Island Hospital, Providence, RI 02903, USA. Tel.: +1-401-444-5796; fax: +1-401-444-6111.
    Affiliations
    Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI
    Search for articles by this author
  • Gregory E. McEnteggart
    Affiliations
    Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI
    Search for articles by this author
  • Timothy P. Murphy
    Affiliations
    Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI
    Search for articles by this author
  • Ethan Prince
    Affiliations
    Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI
    Search for articles by this author
  • Sun Ahn
    Affiliations
    Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI
    Search for articles by this author
  • Gregory Soares
    Affiliations
    Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI
    Search for articles by this author
Published:February 11, 2015DOI:https://doi.org/10.1016/j.clinimag.2015.02.003

      Abstract

      We conducted a pooled analysis of clinical trials comparing intravenous Fenoldopam (FP) with Saline/Placebo/N-acetyl cysteine (NAC) for the prevention of contrast-induced nephropathy (CIN). Five studies were eligible. Quantitative analyses were done with Review Manager (RevMan version 5.2.). A total of 85 out of 353 patients in Fenoldopam group while 73 among 366 in the control group were affected due to CIN. The risk ratio for the development of CIN in the Fenoldopam group was 1.19 compared to the control group. This was not statistically significant. Fenoldopam is no better than Placebo/Saline or NAC in preventing CIN, but more studies are required.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Waybill MM
        • Waybill PN
        Contrast media-induced nephrotoxicity: Identification of patients at risk and algorithms for prevention.
        J Vasc Interv Radiol. 2001; 12: 3-9
        • McDonald RJ
        • McDonald JS
        • Brida JP
        • Carter RE
        • Fleming CJ
        • Misra S
        • et al.
        Intravenous contrast material-induced nephropathy: Causal or coincident phenomenon?.
        Radiology. 2013; 267: 106-118
        • Katzberg RW
        • Lamba R
        Contrast induced nephropathy after intravenous administration: Fact or fiction?.
        Radiol Clin North Am. 2009; 47: 789-800
        • Romano G
        • Briguori C
        • Quintavalle C
        • Zanca C
        • Rivera NV
        • Colombo A
        • et al.
        Contrast agents and renal cell apoptosis.
        Eur Heart J. 2008; 29: 2569-2576
        • Chong E
        • Shen L
        • Poh KK
        • Tan HC
        Risk scoring system for prediction of contrast-induced nephropathy in patients with preexisting renal impairment undergoing percutaneous coronary intervention.
        Singapore Med J. 2012; 53: 164-169
      1. Contrast induced nephropathy.
        in: ACR Manual on Contrast Media, Version 9. ACR Committee on Drugs and Contrast Media. American College of Radiology, 2013 ([Web site: http://www.acr.org/Quality-Safety/Resources/Contrast-Manual. Published 2013, Accessed: December 2013])
        • Seeliger E
        • Sendeski M
        • Rihal CS
        • Persson PB
        Contrast-induced kidney injury: Mechanisms, risk factors and prevention.
        Eur Heart J. 2012; 33: 2007-2015
        • Allaqaband S
        • Tumuluri R
        • Malik AM
        • Gupta A
        • Volkert P
        • Shalev Y
        • et al.
        Prospective randomized study of N-acetylcysteine, Fenoldopam, and Saline for prevention of radiocontrast-induced nephropathy.
        Catheter Cardiovasc Interv. 2002; 57: 279-283
        • Briguori C
        • Colombo A
        • Airoldi F
        • Violante A
        • Castelli A
        • Balestrieri P
        • et al.
        N-Acetylcysteine versus Fenoldopam Mesylate to prevent contrast agent-associated nephrotoxicity.
        J Am Coll Cardiol. 2004; 44: 762-765
        • Ng TMH
        • Shurmur SW
        • Silver M
        • Nissen LR
        • O’Leary EL
        • Rigmaiden RS
        • et al.
        Comparison of N-acetylcysteine and Fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
        Int J Cardiol. 2006; 109: 322-328
        • Stone GW
        • McCollough PA
        • Tumlin JA
        • Lepor NE
        • Madyoon H
        • Murray P
        • et al.
        Fenoldopam Mesylate for the prevention of contrast-induced nephropathy. A randomized controlled trial.
        J Am Med Assoc. 2003; 290: 2284-2291
        • Tumlin JA
        • Wang A
        • Murray PT
        • Mathur VS
        Fenoldopam mesylate blocks reduction in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy.
        Am Heart J. 2002; 143: 894-903
        • Asif A
        • Epstein DL
        • Epstein M
        Dopamine-1 receptor agonist: Renal effects and its potential role in the management of radiocontrast-induced nephropathy.
        J Clin Pharmacol. 2004; 44: 1342-1351
        • Landoni G.
        • Biondi-Zoccai G.G.
        • Marino G.
        Bove T, Fochi O, MajG, et al.
        Fenoldopam reduced the need for renal replacement therapy and in-hospital death in cardiovascular surgery: A meta-analysis, J Cardiothorac Vasc Anesth. 2008; 22: 27-33
        • Moher D
        • Liberati A
        • Tetzlaff J
        • Altman DJ
        Preferred reporting items for systematic reviews and meta-analysis. The PRISMA statement.
        PLoS Med. 2009; 6: e1000097
        • DerSimonian R
        • Laird N
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Sendeski MM
        • Persson AB
        • Liu ZZ
        • Busch JF
        • Weikert S
        • Persson PB
        • et al.
        Iodinated contrast media cause endothelial damage leading to vasoconstriction of human and rat vasa recta.
        Am J Physiol Renal Physiol. 2012; 303: F1592-F1598
        • Bakris GL
        • Lass NA
        • Glock D
        Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role of dopamine-1 receptors.
        Kidney Int. 1999; 56: 206-210
        • Allison NL
        • Dubb JW
        • Ziemniack JA
        • Alexander F
        • Stote RM
        The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics.
        Clin Pharmacol Ther. 1987; 41: 282-288
        • Mathur VS
        • Swan SK
        • Lambrecht LJ
        • Anjum S
        • Fellmann J
        • McGuire D
        • et al.
        The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects.
        Crit Care Med. 1999; 27: 1832-1837
        • McDonald RH
        • Goldberg LI
        • McNay JL
        • Tuttle EP
        Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate and renal plasma flow.
        J Clin Invest. 1964; 43: 1116-1124
        • Kini AS
        • Mitre CA
        • Kamran M
        • Suleman J
        • Kim M
        • Duffy ME
        • et al.
        Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.
        Am J Cardiol. 2002; 89: 999-1002
        • Kini AS
        • Mitre CA
        • Kim M
        • Kamran M
        • Reich D
        • Sharma SK
        A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: Effect of selective dopamine receptor agonist Fenoldopam.
        Catheter Cardiovasc Interv. 2002; 55: 169-173
        • Loomba RS
        • Shah PH
        • Aggarwal S
        • Arora RR
        Role of N-acetylcysteine to prevent contrast-induced nephropathy: A Meta-analysis.
        Am J Ther. 2013; ([Epub ahead of print])
        • Sun Z
        • Fu Q
        • Cao L
        • Jin W
        • Cheng L
        • Li Z
        Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: A meta-analysis of randomized controlled trials.
        PLoS One. 2013; 8: e55124
        • Roberts R
        Hemodynamic effects of an oral dopamine receptor agonist (Fenoldopam) in patients with congestive heart failure.
        J Am Coll Cardiol. 1985; 6: 792-796